deutetrabenazine; tetrabenazine D6 (Austedo)
Jump to navigation
Jump to search
Indications
- treatment of Huntington's chorea (FDA-approved April 2017)
Contraindications
- suicidal ideation
- hepatic impairment
- concurrent administration of: MAOI, reserpine, tetrabenazine
Dosage
- start 6 mg PO QD
- max: 24 mg PO BID
- BID dosing >= 12 mg QD
- administer with food
- swallow tablets whole; do not chew, crush, or break
Tabs: 6 mg, 9 mg, 12 mg
Adverse effects
- common (> 8%)
Drug interactions
- strong CYP2D6 inhibitors
- alcohol or sedative may increase somnolence, sedation
Mechanism of action
- inhibits vesicular monoamine 2 transporter (VMAT2)
More general terms
References
- ↑ Fiore K FDA Okays First Tardive Dyskinesia Drug - VMAT2 inhibitor diminished abnormal involuntary movements in pivotal trial. MedPage Today. April 11, 2017 https://www.medpagetoday.com/Neurology/GeneralNeurology/64513
Brooks M FDA Clears Deutetrabenazine (Austedo) for Huntington's Chorea. Medscape - Apr 04, 2017 http://www.medscape.com/viewarticle/8781621
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Huntington Study Group, Frank S, Testa CM, Stamler D et al Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 5;316(1):40-50. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27380342 Free Article
- ↑ Highlights of Prescribing Information Austedo (deutetrabenazine) https://www.austedo.com/pi